(98 days)
Light therapy to provide topical heating for:
Temporary increase in local blood circulation Temporary relief of minor muscle and joint aches, pains and stiffness Relaxation of muscles Muscle spasms Minor pain and stiffness associated with arthritis
The Dynatron Tri-wave™ light pad and Dynatron Tri-wave™ light probe generate therapeutic topical heating treatments through the medium of multi-wavelength light energy to targeted tissue.
The Dynatron Tri-wave™ light pad is a bifurcated pad with two 5" x 7" treatment pads connected by a 24" cable between them and a 72" cable connecting to the Dynatron Solaris plus™ controlling console. The two pads accommodate treating both sides of a shoulder, elbow, knee, etc. or may be used side by side to treat larger areas such as the lower back.
The Dynatron Tri-wave™ light probe is designed with super luminous diodes emitting three different wavelengths of light. The Infrared LEDs have a wavelength of 850nm, the Red LEDs have a wavelength of 624nm and the Blue LEDs have a wavelength of 464nm. The light probe handle has an ergonomic design and is suited for treating small areas such as the hand, wrist or neck.
The provided text from K113250 describes a 510(k) premarket notification for the Dynatron Tri-wave™ light pad and probe. This document focuses on demonstrating substantial equivalence to predicate devices rather than proving specific performance against acceptance criteria in a clinical study for a new device.
Therefore, many of the typical questions regarding acceptance criteria, study design, sample sizes, expert ground truth, and MRMC studies are not applicable in the context of this 510(k) submission.
Here's an breakdown based on the information available:
1. A table of acceptance criteria and the reported device performance
This information is not provided in the document. The submission focuses on demonstrating substantial equivalence to predicate devices, which implies that the new device performs similarly and is as safe and effective as the already-cleared devices. No specific "acceptance criteria" in terms of numerical performance metrics (e.g., sensitivity, specificity, accuracy for a diagnostic device) are mentioned for the Dynatron Tri-wave™ light pad and probe. Its performance is implicitly accepted if it performs similarly to the predicate devices.
2. Sample sized used for the test set and the data provenance
Not applicable. This submission does not describe a new clinical performance study with a test set of data. It relies on the established safety and effectiveness of its predicate devices.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable. There is no described test set requiring expert ground truth establishment.
4. Adjudication method for the test set
Not applicable. There is no described test set requiring adjudication.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This device is a light therapy device, not an AI-powered diagnostic or assistive tool. Therefore, an MRMC study and AI assistance are not relevant to this submission.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This device is a hardware device for light therapy, not an algorithm.
7. The type of ground truth used
Not applicable. As there is no de novo performance study, there is no ground truth established for the new device's performance against specific criteria. The ground truth, in a broader sense for this type of submission, is the established safety and effectiveness of the predicate devices.
8. The sample size for the training set
Not applicable. This device is a hardware device; machine learning training sets are not relevant here.
9. How the ground truth for the training set was established
Not applicable. As per point 8, there is no training set for this device.
Summary of the Study that Proves the Device Meets Acceptance Criteria (as per the 510(k) Submission):
The "study" in this context is the substantiation of substantial equivalence to legally marketed predicate devices, as documented in the 510(k) submission.
- Mechanism of Proof: The submission aims to prove that the Dynatron Tri-wave™ light pad and probe are substantially equivalent to the Dynatron Xp Infrared Pad (K051261) and D880 Infrared Probe (K031329), respectively.
- Basis for Equivalence:
- Intended Use/Indications For Use: The indications for use for the Dynatron Tri-wave™ devices are stated to be "consistent with the cleared indications for the predicate devices" (temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness, relaxation of muscles, muscle spasms, minor pain and stiffness associated with arthritis).
- Technological Characteristics: The new devices generate therapeutic topical heating through multi-wavelength light energy (Infrared, Red, Blue LEDs). While the predicate devices operate with one primary wavelength, the submission likely argues that the addition of wavelengths does not raise new questions of safety or effectiveness, or that the overall effect is still comparable. The controls and power mechanisms are stated to be the same as the predicate devices.
- Safety and Effectiveness: The submission states, "There are no substantive differences between the products defined in this 510(k) submission and the predicate devices. They are similar to the technologies that are currently used in other similar medical devices." It further mentions that the devices are developed under Dynatronics' Quality Management System, subject to design/change control, and verification/validation to applicable standards. This implies that the accepted safety and effectiveness of the "predicate" device's technology form the basis for accepting the new device's safety and effectiveness.
In essence, the acceptance criteria are largely centered on demonstrating that the new device is as safe and effective as the existing predicate devices, and that any technological differences do not introduce new safety or efficacy challenges. The "study" proving this is the careful comparison of the new device's specifications and intended use against those of the predicate devices.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for Dynatronics. The logo features a stylized "D" followed by the company name in a bold, sans-serif font. Below the logo is the address "7030 Park Centre Drive • Salt Lake City, Ut 84121" and the phone and fax numbers "800-874-6251 • fax 801-568-7711".
FEB - 9 2012
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
26 October 2011
SUBMITTED BY: DYNATRONICS CORPORATION 7030 Park Centre Drive Salt Lake City UT 84121 Phone: (800) 874-6251; (801) 568-7000 Fax: (801) 568-7711
1. DEVICE NAME:
Trade Name(s):
Common Name: Classification: Regulation Nos .: Product Codes:
Dynatron Tri-wave™ light pad (model number DLP3) Dynatron Tri-wave™ light probe (model number DCP3) Topical heat lamp Class II 890.5500 ILY
2. PREDICATE DEVICES:
Dynatron Xp Infrared Pad, cleared under K051261 (July 25, 2005) as the predicate for the Dynatron Tri-wave™ light pad
D880 Infrared Probe, cleared under K031329 (Oct 22, 2003) as predicate for the Dynatron Tri-wave™ light probe
3. DESCRIPTION:
The Dynatron Tri-wave™ light pad and Dynatron Tri-wave™ light probe generate therapeutic topical heating treatments through the medium of multi-wavelength light energy to targeted tissue.
The Dynatron Tri-wave™ light pad is a bifurcated pad with two 5" x 7" treatment pads connected by a 24" cable between them and a 72" cable connecting to the Dynatron Solaris plus™ controlling console. The two pads accommodate treating both sides of a shoulder, elbow, knee, etc. or may be used side by side to treat larger areas such as the lower back.
The Dynatron Tri-wave™ light probe is designed with super luminous diodes emitting three different wavelengths of light. The Infrared LEDs have a wavelength of 850nm, the Red LEDs have a wavelength of 624nm and the Blue LEDs have a wavelength of 464nm. The light probe handle has an ergonomic design and is suited for treating small areas such as the hand, wrist or neck.
Accessories:
Protective eyewear
Page 1 of 3
. . . .
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for Dynatronics. The logo consists of a stylized letter "D" followed by the word "Dynatronics" in a bold, italicized font. Below the logo is the address "7030 Park Centre Drive • Salt Lake City, Ut 84121" and the phone number "800-874-6251 • fax 801-568-7711".
4. INTENDED USE/INDICATIONS FOR USE:
The Dynatron Tri-wave™ light pad and Dynatron Tri-wave Light™ Probe use light therapy to provide topical heating for the following indications:
Temporary increase in local blood circulation Temporary relief of minor muscle and joint aches, pains and stiffness Relaxation of muscles Muscle spasms Minor pain and stiffness associated with arthritis
The Intended Use/Indications For Use stated herein are consistent with the cleared indications for the predicate devices.
5. TECHNICAL ANALYSIS:
The Dynatron Tri-wave™ light pad and Dynatron Tri-wave™ light probe generate therapeutic benefit as described in allowed claims through the delivery of mulitwavelengths of light:
Infrared (850nm) Red (624nm) Blue (464nm)
The predicate pad and probe operate with one primary wavelength of light.
Controls and power for the Dynatron Tri-wave™ light pad and Dynatron Tri-wave™ light probe are the same as with the predicate devices via a controlling console. Pause and restart functions for the Dynatron Tri-wave™ light probe are activated by user interface on the probe but controlled by Dynatron Solaris PLUS™ controlling console. Treatment setup, start and stop functions for the Dynatron Tri-wave™ light pad are controlled by the Dynatron Solaris PLUSTM controlling console user interface.
Performance characteristics:
Dynatron Tri-wave™ light pad is comprised of the following recommended treatment combinations:
Infrared (850nm) and Red (624nm) Blue (464nm) and Infrared (850nm) Blue (464nm), Infrared (850nm) and Red (624nm) Infrared (850nm) only
Dynatron Tri-wave™ light probe is comprised of the following recommended treatment combinations:
Infrared (850nm) and Red (624nm) Blue (464nm) and Infrared (850nm) Blue (464nm) Infrared (850nm), and Red (624nm) Infrared (850nm) only
Page 2 of 3
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for Dynatronics. The logo features a stylized letter "D" followed by the company name in a bold, italicized font. Below the logo is the company's address, which is 7030 Park Centre Drive, Salt Lake City, UT 84121, as well as their phone number, 800-874-6251, and fax number, 801-568-7711.
6. SUBSTANTIAL EQUIVALENCE (SE) RATIONALE:
The Dynatron Tri-wave™ light probe and Dynatron Tri-wave™ light pad provide topical heating for treatment of selected medical conditions and share the same or similar basic characteristics, features and intended uses as the predicates and, therefore, are substantially equivalent to the Dynatron Xp pad and Dynatron D880 light probe (applicable 'K' numbers listed above).
7. SAFETY AND EFFECTIVENESS SUMMARY:
There are no substantive differences between the products defined in this 510(k) submission and the predicate devices. They are similar to the technologies that are currently used in other similar medical devices. They are subject to development and documentation under Dynatronics' mature Quality Management System, under the Quality System Regulation, 21 CFR Part 820, under design/change control, and are subject to verification and validation to applicable standards/guidance documents. The Dynatron Tri-wave™ light family of multi-wavelengh light therapy devices are safe and effective when used as indicated in specific applications under a clinician's supervision/therapy program.
Signed:
: Douglas G. Samson
Douglas Sampson, VP, R&D and Operations DYNATRONICS CORPORATION
Dated: 26 OCTOBER 2011
Page 3 of 3
{3}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized image of an eagle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
FEB - 9 2012
Dynatronics Corporation % Mr. Douglas Sampson 7030 Park Centre Drive Salt Lake City, Utah 84121
Re: K113250
Trade/Device Name: Dynatron Tri-wave™ Light Pad Dynatron Tri-wave™ Light Probe Regulation Number: 21 CFR 890.5500 Regulation Name: Infrared lamp Regulatory Class: Class II Product Code: ILY Dated: January 25, 2012 Received: January 30, 2012
Dear Mr. Sampson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
{4}------------------------------------------------
Page 2 – Mr. Douglas Sampson
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
Indications for Use Statement
510(k) Number (if known): K113250
Dynatron Tri-wave™ light pad Device Name: Dynatron Tri-wave™ light probe
Indications for Use:
Light therapy to provide topical heating for:
Temporary increase in local blood circulation Temporary relief of minor muscle and joint aches, pains and stiffness Relaxation of muscles Muscle spasms Minor pain and stiffness associated with arthritis
Prescription Use __ X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use _ (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Milke Ogden for nxn
(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K113250 Page 1 of 1
§ 890.5500 Infrared lamp.
(a)
Identification. An infrared lamp is a device intended for medical purposes that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.(b)
Classification. Class II (special controls). The device, when it is an infrared therapeutic heating lamp, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 890.9.